No Data
No Data
BriaCell Receives And Executes Letter Of Intent To Advance Clinical Development Of Breast And Prostate Cancer Immunotherapies
Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+ (prostate cancer), BriaCell's novel off-the-shelf personalized cancer va
BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies
BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference
PHILADELPHIA and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that
BriaCell Provides Update On Alleged Illegal Trading of Public Securities
PHILADELPHIA and VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechno
BriaCell Reports Prelim Disease Control Rate Of 61% In Evaluable Phase 2 Advanced Breast Cancer Patients Treated With Briacell's Bria-imt Regimen; Control Rate Of 50% Reported In Evaluable Patients Who Failed Prior ADC Therapy
Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell's pivotal Phase 3 studyDisease control rate of 50% in evaluable patients treated with t
BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case
Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell's pivotal Phase 3 study Disease control rate of 50% in evaluable patients treated with the Phase 3
No Data